CompletedNCT01299454

A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

Medication studyAges 18+United StatesSchizophrenia

The study in practice

Understand this study

Listed age limits: from 18 years.

Listed locations: Miami and 2 more locationsSee all locations and recruitment
Study phase: Phase 1

Study clarity

Study start dateDecember 2010

Recruitment status: Completed
Enrollment listed in the registry: 45
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United States
Age range: Over 18 Years
Official registry ID: NCT01299454
Official title: Show the full official title
A Single-dose, Open-label, Parallel Group, Matched Study Evaluating the Pharmacokinetics of Oral OPC-34712 Tablet in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

Completed

Miami · Minneapolis · San Antonio

FAQ

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including OPC-34712.

Who was this study for?

Listed age limits: from 18 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.